Pentixapharm Holding AG

As of June 30, 2026, Pentixapharm Holding AG carries a market capitalization of 55.30M, placing it among publicly traded companies globally. Its enterprise value stands at 51.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Pentixapharm Holding AG has 25.86M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1,005.43, and the price-to-book ratio stands at 1.94.

These figures are as of June 30, 2026. The EV/Sales ratio of 940.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 51.70M versus a market cap of 55.30M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pentixapharm Holding AG maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Pentixapharm Holding AG posted a negative return on equity (ROE) of -43.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.55, reflecting losses generated across the asset base. The company generates approximately 973.45 in revenue per employee across its workforce of 56.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Pentixapharm Holding AG recorded an income tax benefit of -2.78M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -17.82M and -15.03M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Pentixapharm Holding AG's stock has gained approximately 6.34% over the past 52 weeks. The 50-day moving average sits at 1.84, while the 200-day moving average is 1.92.

Over the twelve months ended June 30, 2026, Pentixapharm Holding AG generated 55,000.00 in revenue and converted that into -15.03M in net income, yielding earnings per share of -0.58. EBITDA reached -14.04M, while operating income came in at -17.53M.

These figures are as of June 30, 2026. Total book value stands at 28.47M, with working capital of 1.65M providing operational flexibility.

Pentixapharm Holding AG produced -14.60M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7,000.00 in capital expenditures, free cash flow totaled -14.61M - equivalent to -0.56 per share.

Over the twelve months ended June 30, 2026, Pentixapharm Holding AG posted a gross margin of -9,521.82, reflecting its pricing power and cost economics. The operating margin of -31,878.18 and net profit margin of -27,330.91 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -26.41: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.23, meaning Pentixapharm Holding AG raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Pentixapharm Holding AG's most recent stock split took place on July 3, 2026 with a 698:741 split ratio.

As of June 30, 2026, Pentixapharm Holding AG has an Altman Z-Score of -9.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.